Evofem Biosciences (EVFM)
(Delayed Data from OTC)
$0.01 USD
0.00 (1.02%)
Updated Jul 12, 2024 01:41 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
EVFM 0.01 0.00(1.02%)
Will EVFM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EVFM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EVFM
Why Endo (ENDP) Stock Wilted After its Surge on Tuesday?
EVFM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for EVFM
Evofem gains on new U.S. patent covering Phexxi composition of matter
EVFM Stock Earnings: Evofem Biosciences Reported Results for Q1 2024
Evofem Biosciences GAAP EPS of -$0.16, revenue of $3.6M
Evofem Biosciences: Contractual Agreements Initiated and Terminated